Table 2.
Summary of clinical trials with nelarabine administration in T-cell malignancies.
| Trial | Kurzberg et al 200514 | DeAngelo et al 200721 | Goy et al 200322 | Berg et al 200523 | Czuczman et al 200724 | Gandhi et al 200825 | Commander et al 201026 |
|---|---|---|---|---|---|---|---|
| Evaluable patientsa | 39 | 39 | 17 | 106 | 19 | 11 | 7 |
| Diagnosis | T-ALL, T-LBL | T-ALL, T-LBL | T-LBL | T-ALL, T-LBL | Cutaneous and peripheral T-LBL | T-PLL | T-ALL, T-LBL |
| Outcomes (%)b | |||||||
| CR | 23.1% | 30.8% | 11.8% | 26.4% | 0% | 5.7%c | 71.4% |
| PR | 30.8% | 10.3% | 35.3% | 8.5% | 10.5% | 28.6%c | 28.6% |
Notes:
a
With T-cell malignancy receiving nelarabine;
b
Includes all diagnoses and trial doses;
c
Includes patients with B-cell lymphocytic leukemia as numbers were not reported per diagnosis.
Abbreviations: T-ALL, T-cell acute lymphoblastic leukemia; T-LBL, T-cell lymphoblastic lymphoma; T-PLL, T-cell prolymphocytic leukemia; CR, complete response; PR, partial response.